Since Abide’s inception in 2011, we have formed alliances with major pharmaceutical companies and top-tier biotechnology companies, as well as leading academic laboratories and research foundations. We have a continuing interest in collaborating with partners who have unique biological expertise and capabilities in therapeutic areas where modulation of serine hydrolases can play a role in treating diseases with unmet medical need.

Current Collaborations

The Scripps Research Institute (TSRI)

Abide’s platform is based on technology developed at TSRI by Professors Benjamin Cravatt and Dale Boger. The Cravatt lab’s research on activity-based protein profiling (ABPP) is the conceptual foundation on which Abide was formed, as this work enables the identification and validation of novel serine hydrolase targets for the treatment of human disease. Abide entered into a collaboration with TSRI in November 2011. The Cravatt lab continues to serve as Abide’s key academic partner, providing pioneering research on serine hydrolase biology.


In February 2014, Abide entered into a strategic collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology. In connection with the collaboration, Abide received an upfront payment and Celgene took an equity stake in Abide and retains an exclusive option to acquire the company. Abide stands to receive developmental and regulatory milestone payments if Celgene exercises its option to license certain rights on products resulting from the collaboration. During the collaboration, Abide will apply its technology platform, which selectively and near-universally targets the serine hydrolase family, to discover new therapeutic targets and drug candidates for the treatment of inflammatory and immunological disorders.

In September 2016, Celgene exercised its option to obtain ex-US rights to Abide’s first-in-class endocannabinoid system modulator, ABX-1431, for the treatment of neurological disease. ABX-1431 is an orally active, selective, small molecule inhibitor of monoacylglycerol lipase (MGLL) that modulates the levels of the endogenous cannabinoid, 2-arachidonoylglycerol (2-AG), which in turn regulates neurotransmitter balance and inflammation.

Celgene will be responsible for development costs for ABX-1431 in all indications from Phase 2 and beyond, while Abide will conduct a number of Phase 1b studies to continue to explore indications where endocannabinoid modulation may effect disease progression.


In November 2014, Abide entered into a collaboration with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases. Under the terms of the agreement, Abide and Oxford will explore the role of monoacylglycerol lipase (MGLL) inhibitors in altering endocannabinoid tone in the human brain. The collaboration will combine the unique domain experience and capabilities at Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), under the directorship of Professor Irene Tracey with Abide’s unique chemoproteomics platform. The goals of the collaboration are to explore MGLL in a number of clinical indications and to discover novel serine hydrolase targets utilizing samples from patients with inflammatory conditions in collaboration with Professors Alison Simmons and Peter Taylor.

Tourette Association of America

Abide Therapeutics and the Tourette Association of America (TAA) established a collaboration in February 2017 to advance the development of treatments for patients with Tourette. Through this collaboration, Abide will connect with healthcare professionals and patient advocates to gain a better understanding of the unmet needs in the Tourette community. Abide has recently initiated a study to evaluate ABX-1431 as a potential symptomatic treatment for Tourette Syndrome patients. ABX-1431 works through the body’s natural endocannabinoid pathway to enhance the brain’s attempt to equalize the imbalance that is thought to play a role in the pathophysiology of Tourette Syndrome. It is hoped that ABX-1431 will utilize this pathway more safely and effectively than natural cannabinoids, such as cannabis, to reduce tics associated with Tourette Syndrome and also potentially impact co-morbid conditions such as Obsessive Compulsive Disorder (OCD) and Attention Deficit Hyperactivity Disorder (ADHD). The TAA is pleased to collaborate with Abide in its efforts to engage in evidence-based, safe and effective treatment studies for individuals living with Tourette and related disorders.


Abide’s vision is to be the partner of choice in the discovery and development of serine hydrolase therapeutics. We work with our partners to deliver first-in-class innovative therapeutics with the potential to change patients’ lives.

If you are interested in partnering with Abide, please contact us.